Clinical Trials | September 23, 2025
Teva unveils promising SOLARIS resultsfor Olanzapine LAI
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
Subscribe To Our Newsletter & Stay Updated
